Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 5/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 4/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM4B | O94953 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10851083 | 0.83 | HTR2B (0.42) | HTR2BADRA1AADRA2AF10 | |
| SCHEMBL5255708 | 0.81 | ADRA1A (0.51) | HTR2BADRA1AADRA2AADRA1DADRA1B | |
| SCHEMBL196337 | 0.78 | — | — | |
| SCHEMBL7983041 | 0.77 | HTR2B (0.45) | HTR2BADRA1AHRH3KDM4AKDM4B | |
| SCHEMBL8077368 | 0.76 | ADRA1A (0.46) | HTR2BADRA1AADRA2AADRA1DADRA1B | |
| SCHEMBL7809418 | 0.74 | ADRA1A (0.52) | HTR2BADRA1AADRA2AADRA1DADRA1B | |
| SCHEMBL4585762 | 0.74 | ADRA1A (0.52) | HTR2BADRA1AADRA2AADRA1DADRA1B | |
| SCHEMBL184451 | 0.74 | ADRA1A (0.55) | HTR2BADRA1AADRA2AADRA1DADRA1B | |
| SCHEMBL1494449 | 0.74 | — | — | |
| SCHEMBL18057110 | 0.73 | HRH3 (0.43) | HRH3PARP1PARP2KDM4AKDM4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200316032-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING RETINAL PIGMENT EPITHELIUM DEGENERATION AND METHODS USING THE SAME | THE SCHEPENS EYE RESEARCH, INSTITUTE, INC. | 2020-10-08 | — | — | US | disclosed |
| WO-2018067615-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| WO-2001057038-A9 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS PARP INHIBITORS | BASF AG (DE) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316032-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING RETINAL PIGMENT EPITHELIUM DEGENERATION AND METHODS USING THE SAME | ALDH1A2, RBP4, RBP1 | HTR2B 4175/4885ADRA1A 3423/4885HRH3 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.